Four anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies are approved for migraine prevention. To ensure clinicians are prepared to consider these agents when clinically indicated, this educational activity will compare the efficacy and safety of these therapies for migraine prevention and discuss strategies for shared decision-making.
Cynthia E. Armand, MD, Assistant Professor of Neurology Albert Einstein College of Medicine, Fellowship Director Montefiore Headache Center, Bronx, NY
Carrie Dougherty, MD, FAHS, Associate Professor of Neurology Program Director, Headache Medicine Fellowship, Assistant Program Director, Neurology Residency MedStar Georgetown University Hospital, Washington, DC
Click here to view this activity:
